Literature DB >> 11751384

Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.

H Biliran1, S Sheng.   

Abstract

Maspin is a novel serine protease inhibitor with tumor suppressive activity, inhibiting tumor invasion and metastasis. To date, the underlying molecular mechanism of maspin remains elusive. Recombinant maspin has been shown to specifically inhibit cell surface-associated urokinase-type plasminogen activator (uPA) and fibrinogen-bound tissue-type plasminogen activator. However, the role of endogenous maspin in plasminogen activation is totally unknown. To address this issue, we generated stable maspin-expressing transfectants using prostate carcinoma cells DU145 as the parental cell line. We report here that endogenous maspin exerts pleiotropic inhibitory effects on the pericellular uPA system. Maspin expression led to a significantly reduced level of cell surface-bound uPA and uPA receptor proteins without altering the steady-state levels of the respective mRNAs. Treatment with receptor-associated protein (RAP), a specific inhibitor of low-density lipoprotein receptor-related protein, lead to a significantly increased level of secreted uPA and cell surface uPAR in maspin transfectants but not in the mock control cells. A combination of enzymatic and molecular analyses revealed that maspin inhibits the cell surface-mediated plasminogen activation by forming an SDS-resistant complex with cell surface-bound uPA. In addition, maspin expression led to a dramatic reduction in the release of active uPA, both high molecular weight and the low molecular weight, into the conditioned culture medium. Consistently, the conditioned medium of maspin transfectant clones had a significantly reduced activity in converting plasminogen to plasmin. The inhibitory effect of maspin on pericellular uPA correlates with significantly decreased cell invasion potential and motility in vitro. The maspin-neutralizing antibody (Abs4A) reversed the subdued invasive potential of maspin transfectant cells in a dose-dependent manner. In summary, this study provides the first evidence that endogenous maspin is a potent inhibitor of pericellular uPA. Furthermore, our results support a current hypothesis that maspin blocks tumor invasion and motility by inhibiting localized pericellular proteolysis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751384

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Simultaneous evaluation of maspin and CXCR4 in patients with breast cancer.

Authors:  Efthimia Tsoli; Petros K Tsantoulis; Alexandros Papalambros; Branko Perunovic; David England; David A Rawlands; Gary M Reynolds; Dimitrios Vlachodimitropoulos; Susan L Morgan; Chara A Spiliopoulou; Thanos Athanasiou; Vassilis G Gorgoulis
Journal:  J Clin Pathol       Date:  2006-06-02       Impact factor: 3.411

Review 2.  The natural tumor suppressor protein maspin and potential application in non small cell lung cancer.

Authors:  Fulvio Lonardo; Xiaohua Li; Alexander Kaplun; Ayman Soubani; Seema Sethi; Shirish Gadgeel; Shijie Sheng
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

3.  Identification of differentially expressed genes in mouse hepatocarcinoma ascites cell line with low potential of lymphogenous metastasis.

Authors:  Xiao-Nan Cui; Jian-Wu Tang; Li Hou; Bo Song; Li-Ying Ban
Journal:  World J Gastroenterol       Date:  2006-11-14       Impact factor: 5.742

Review 4.  The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin.

Authors:  Margarida M Bernardo; Sijana H Dzinic; Maria J Matta; Ivory Dean; Lina Saker; Shijie Sheng
Journal:  J Cell Biochem       Date:  2017-03-21       Impact factor: 4.429

Review 5.  Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases.

Authors:  Thomas J Wilson; Rakesh K Singh
Journal:  Biochim Biophys Acta       Date:  2007-11-26

6.  Maspin increases extracellular plasminogen activator activity associated with corneal fibroblasts and myofibroblasts.

Authors:  Debra J Warejcka; Malathi Narayan; Sally S Twining
Journal:  Exp Eye Res       Date:  2011-07-27       Impact factor: 3.467

7.  HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.

Authors:  Xiaohua Li; Alexander Kaplun; Fulvio Lonardo; Elisabeth Heath; Fazlul H Sarkar; Jonathan Irish; Wael Sakr; Shijie Sheng
Journal:  Mol Cancer Res       Date:  2011-05-26       Impact factor: 5.852

8.  Internalization by multiple endocytic pathways and lysosomal processing impact maspin-based therapeutics.

Authors:  Thomas M Bodenstine; Richard E B Seftor; Elisabeth A Seftor; Zhila Khalkhali-Ellis; Nicole A Samii; J Cesar Monarrez; Grace S Chandler; Philip A Pemberton; Mary J C Hendrix
Journal:  Mol Cancer Res       Date:  2014-09-25       Impact factor: 5.852

Review 9.  Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.

Authors:  Shijie Sheng; M Margarida Bernardo; Sijana H Dzinic; Kang Chen; Elisabeth I Heath; Wael A Sakr
Journal:  Cancer Metastasis Rev       Date:  2018-12       Impact factor: 9.264

Review 10.  Tumor suppressor maspin as a modulator of host immune response to cancer.

Authors:  Sijana H Dzinic; Maria M Bernardo; Daniel S M Oliveira; Marian Wahba; Wael Sakr; Shijie Sheng
Journal:  Bosn J Basic Med Sci       Date:  2015-10-25       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.